WO2026021516 - SUBSTITUTED ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/021516
Publication Date
29.01.2026
International Application No.
PCT/CN2025/110261
International Filing Date
24.07.2025
Title **
[English]
SUBSTITUTED ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST AND USE THEREOF
[French]
ANTAGONISTE DU RÉCEPTEUR DE L'ANGIOTENSINE ET DE L'ENDOTHÉLINE SUBSTITUÉ ET SON UTILISATION
[Chinese]
一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
LAI, Yingjie
WANG, Bin
TIAN, Zebing
YUE, Xiaoliang
XIANG, Jiehao
SU, Shaobin
ZHU, Xiaoli
XIAO, Ying
DUAN, Zhenfang
LIU, Wenjuan
Priority Data
202411008593.6
25.07.2024
CN
202411445380.X
15.10.2024
CN
202411816917.9
09.12.2024
CN
202510890347.6
30.06.2025
CN
202510983420.4
16.07.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2207 | |
| EPO | Filing, Examination, Granting | 12846 | |
| Japan | Filing, Examination, Granting | 2213 | |
| South Korea | Filing, Examination, Granting | 2231 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,237
Abstract[English]
The present invention relates to the technical field of chemical drugs, and provides a substituted angiotensin and endothelin receptor antagonist compound, and a preparation method therefor and a medical use thereof.[French]
La présente invention relève du domaine technique des médicaments chimiques, et concerne un composé antagoniste du récepteur de l'angiotensine et de l'endothéline substitué, son procédé de préparation et son utilisation médicale.[Chinese]
本发明属于化学药物技术领域，提供了一种取代的血管紧张肽和内皮肽受体拮抗剂化合物及其制备方法和医药用途。